The British Journal of Psychiatry · 2003 · 62 citations · 11 references
PharmacyPharmacotherapyPsychiatryPharmacoeconomic ModelingPsychopharmacologyResource Utilization AnalysisAntipsychotic PharmacotherapyAntipsychotic TherapyPharmacoeconomic EvaluationPharmacoepidemiologySchizophrenia PharmacotherapyTreatment-resistant Psychiatric DisordersClozapine PharmacologyMedication Therapy Cost AssessmentTreatment-resistant Psychosis
BACKGROUND: Schizophrenia is a major cause of suicide, and symptoms characteristic of treatment-resistant disease are strong risk factors. Clozapine reduces symptoms in 60% of such patients and significantly decreases the risk of suicide. AIMS: To model the impact of increased clozapine prescribing on lives saved and resource utilisation. METHOD: A model was built to compare current levels of clozapine prescribing with a scenario in which all suitable patients with treatment-resistant schizophrenia received clozapine. RESULTS: It was estimated that an average of 53 lives could be saved in the UK each year. If clozapine is cost-neutral, the cost per life-year saved is pound 5108. If clozapine achieves a 10% reduction in annual support costs, the net saving is pound 8.7 million per annum. An average of 167 acute beds would be freed each year. CONCLUSIONS: The use of clozapine in treatment-resistant schizophrenia saves lives, frees resources and is cost-effective.
11
Active monitoring of 12760 clozapine recipients in the UK and Ireland
Janet Munro, D P O'Sullivan, Christopher Andrews et al. · The British Journal of Psychiatry · 1999 · 286 citations
Medicine, Hematology, Psychiatry +14
Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia
H.Y. Meltzer, Philip A. Cola, Lynne E. Way et al. · American Journal of Psychiatry · 1993 · 211 citations